Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
56. |
ECCT/13/07/03 | Pharmacokinetic and pharmacodynamic studies of efficacy, tolerability and safety of higher dosage rifapentine for treatment of tuberculosis |
Principal Investigator(s) 1. Dr Lena Matata Site(s) in Kenya KEMRI-CDC |
View |
57. |
ECCT/13/07/04 | Advanced Kapsosis Sarcoma Chemotherapy Regimens A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya 1. WRP/KEMRI - Kericho (Kericho county) 2. AMPATH - MOI University Teaching Hospital Eldoret CRS (Uasin Gishu county) |
View |
58. |
ECCT/13/07/05 | Single Dose Escalating, Single-blind Phase 1 Trial in Healthy Male Volunteers to Evalute the Safety, Tolerability and the Pharmacokinetics of Oleylphosphocholine. |
Principal Investigator(s) 1. Rashid Ravasco Juma Site(s) in Kenya KEMRI Centre for Clinical Research |
View |
59. |
ECCT/13/08/01 | M72/AS01 E A phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidatetuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults aged 18-50 years, living in a TB endemic region. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya KEMRI-CDC |
View |
60. |
ECCT/13/08/02 | MalPaC Trial Comparing drug-regimens for clearing parasites in Phase IIb trial designs prior to PCR monitoring for Plasmodium falciparum infection. |
Principal Investigator(s) 1. Caroline Amolo Ogwang 2. Francis Maina Ndung\'u Site(s) in Kenya Junju |
View |